文献速递甲状腺核医学核素与放射性配体治疗

两例TENIS综合征患者99mTc-FAPI-46显著摄取而99mTc-奥曲肽扫描阴性:诊疗一体化应用的新希望

Significant 99mTc-FAPI-46 Uptake in 2 Cases of TENIS Syndrome With Negative Tc-OCTREOTIDE Scan, a New Hope in Theranostic Applications.
PubMed 文献 · Clin Nucl Med · 2025-04-07

本文报告2例分化型甲状腺癌伴甲状腺球蛋白升高而碘闪烁显像阴性(TENIS综合征)患者,均行99mTc-奥曲肽扫描与99mTc-FAPI SPECT/CT评估转移灶。99mTc-奥曲肽扫描未见明显摄取,而99mTc-FAPI-46在转移灶呈强烈摄取;因诊断性扫描显示适当摄取,两例均被认为适合接受177Lu-FAPI-46治疗。

要点

  • 2例TENIS综合征患者99mTc-奥曲肽扫描均未见明显摄取。
  • 99mTc-FAPI-46 SPECT/CT显示转移灶强烈摄取。
  • 因诊断扫描摄取适当,两例被认为适合177Lu-FAPI-46治疗。

核心结论

  • 成纤维细胞激活蛋白抑制剂(FAPI)作为癌症诊断与治疗(诊疗一体化)的新型放射性药物,其作用仍在研究中。
  • 2例TENIS综合征患者99mTc-奥曲肽扫描未见明显摄取,而99mTc-FAPI-46在转移灶显示强烈摄取。
  • 因诊断性扫描显示适当摄取,这两例患者被认为适合接受177Lu-FAPI-46治疗。

研究设计与样本

  • 本文报告2例分化型甲状腺癌伴甲状腺球蛋白升高而碘闪烁显像阴性(TENIS综合征)患者。
  • 两例均行99mTc-奥曲肽扫描与99mTc-FAPI SPECT/CT以评估可能的转移部位。

主要发现

  • 99mTc-奥曲肽扫描在这两例患者中均未见明显摄取。
  • 99mTc-FAPI-46在转移灶呈强烈摄取:一例在肺、肝、肾上腺和腹部淋巴结可见恶性FAPI摄取,另一例在肺部可见。
  • 因诊断性扫描显示适当摄取,这两例患者被认为适合接受177Lu-FAPI-46治疗。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The role of fibroblast activation protein inhibitor (FAPI) as a novel radiopharmaceutical in the field of cancer diagnosis and treatment (theranostic) is still under investigation. We present 2 patients of differentiated thyroid cancer with thyroglobulin elevation and negative iodine scintigraphy (TENIS syndrome) who underwent 99mTc-OCTREOTIDE scan and 99mTc-FAPI SPECT/CT to evaluate possible sites for metastasis. 99mTc-OCTREOTIDE scan showed no remarkable uptake in these patients. On the other hand, foci of metastatic disease were found, with intense 99mTc-FAPI-46 uptake. Malignant FAPI uptake was evident in the lungs, liver, adrenal, and abdominal lymph nodes in a patient and in the lungs of another one. Due to proper uptake in diagnostic scans, these patients were recognized as a suitable candidate for treatment with 177Lu-FAPI-46.

来源:Clin Nucl Med,查看原文。版权归原作者所有。

引用

  1. Ghahraman M, Aryana K, Zakavi SR, et al. Significant 99mTc-FAPI-46 Uptake in 2 Cases of TENIS Syndrome With Negative Tc-OCTREOTIDE Scan, a New Hope in Theranostic Applications. Clin Nucl Med. 2025. PMID: 40179301. doi:10.1097/RLU.0000000000005817

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。